Unknown PHASE1 INTERVENTIONAL 2-arm NCT05024305

Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.

A Multi-center, Phase I, Open Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.

Sponsor: Shandong TheraWisdom Biopharma Co., Ltd.

Conditions Advanced Malignancies

Interventions TWP-102 injection

Updated 5 times since 2021 Last updated: Mar 7, 2022 Started: Mar 8, 2022 Primary completion: Dec 31, 2022 Completion: Jun 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Malignancies, this trial is ongoing. The trial is conducted by Shandong TheraWisdom Biopharma Co., Ltd. and has accumulated 5 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Sep 2023 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Apr 2022 — Sep 2023 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2021 — Apr 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shandong TheraWisdom Biopharma Co., Ltd.

Data source: Shandong TheraWisdom Biopharma Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Harbin, China